TEG®6s system measures the contributions of both platelet count and platelet function to clot formation at the site-of-care

Knowledge of platelet count and function is key to ensuring appropriate hemostatic management. We hypothesized that the novel, portable TEG®6s coagulation assessment system could evaluate the contribution of both platelet count and function to clot formation. Whole-blood samples with variable platel...

Full description

Bibliographic Details
Main Authors: Joao D. Dias, Carlos G Lopez-Espina, Kevin Bliden, Paul Gurbel, Jan Hartmann, Hardean E Achneck
Format: Article
Language:English
Published: Taylor & Francis Group 2020-10-01
Series:Platelets
Subjects:
Online Access:http://dx.doi.org/10.1080/09537104.2019.1704713
Description
Summary:Knowledge of platelet count and function is key to ensuring appropriate hemostatic management. We hypothesized that the novel, portable TEG®6s coagulation assessment system could evaluate the contribution of both platelet count and function to clot formation. Whole-blood samples with variable platelet counts were prepared from healthy volunteers. Platelet function was adjusted using seven concentrations of abciximab and evaluated by light transmission aggregometry (LTA) with TRAP agonist. Maximum amplitude (MA), reaction time (R) and activated clotting time (ACT) were assessed in citrated kaolin (CK), CK with heparinase (CKH), citrated RapidTEG® (CRT), and citrated functional fibrinogen (CFF) assays. Positive correlations were observed between platelet count and CK.MA, CKH.MA, and CRT.MA (p < .0001), and CK.R, CKH.R, and CRT.ACT (p < .05). Platelet count could be accurately quantified in the range 28–91 k/μL, 28–86 k/μL and 28–74 k/μL for CK.MA, CKH.MA, and CRT.MA, respectively. CK.MA, CKH.MA, and CRT.MA showed significant negative relationships with abciximab concentration (p < .001). Platelet function inhibition was detected by all three assays at >68% measured by LTA and quantified in the range 68.4–82% (CK), 69.4–88% (CKH), and 69.7–76% (CRT). This demonstrates the TEG®6s analyzer can accurately evaluate platelet count and function at the site-of-care.
ISSN:0953-7104
1369-1635